NASDAQ:AKBA
Akebia Therapeutics Stock News
$2.24
+0.240 (+12.00%)
At Close: Mar 27, 2024
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
06:31pm, Thursday, 14'th Mar 2024
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago.
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
05:05pm, Monday, 11'th Mar 2024
CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
08:00am, Monday, 20'th Nov 2023
CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, toda
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
11:20am, Thursday, 26'th Oct 2023
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%
03:12pm, Monday, 28'th Aug 2023
If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created t
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
11:16am, Friday, 25'th Aug 2023
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.23 per share a year ago.
Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights
04:35pm, Wednesday, 23'rd Aug 2023
Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass.
Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference
07:45am, Wednesday, 19'th Jul 2023
CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today
Best Stocks For Beginners with Little Money: How To Trade Penny Stocks
12:16pm, Monday, 10'th Jul 2023
There are so many new traders and investors entering the stock market today. But if you're brand new, you might not have a lot of money to invest or don't want to risk a whole lot while you're learnin
Pocket Change, Big Gains: 3 Penny Stocks Ready to Boom
06:07am, Thursday, 06'th Jul 2023
Investors seeking high-growth opportunities often turn their attention to penny stocks, which may have the potential to deliver substantial returns. The three potential high return penny stocks listed
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
10:58am, Monday, 19'th Jun 2023
Here is how Akebia Therapeutics (AKBA) and Haemonetics (HAE) have performed compared to their sector so far this year.
3 Hot Penny Stocks To Watch Before Next Week
02:19pm, Wednesday, 07'th Jun 2023
Penny stocks typically trade for less than $5 and generally belong to small companies often overlooked by mainstream investors. Yet, for those willing to navigate the inherent risks, these cheap stock
All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy
01:09pm, Friday, 02'nd Jun 2023
Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
10:53am, Friday, 02'nd Jun 2023
Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Akebia Therapeutics to Present at Jefferies Healthcare Conference
08:30am, Friday, 02'nd Jun 2023
CAMBRIDGE, Mass. , June 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today